COX-2-Dependent and COX-2-Independent Mode of Action of Celecoxib in Human Liver Cancer Cells
- 1 June 2011
- journal article
- research article
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 15 (6) , 383-392
Abstract
Celecoxib (Celebrex (R) , Pfizer) is a selective cyclooxygenase-2 (COX-2) inhibitor with chemopreventive and antitumor effects. However, it is now well known that celecoxib has several COX-2–independent activities. To better understand COX-2–independent molecular mechanisms underlying the antitumor activity of celecoxib, we investigated the expression profile of the celecoxib-treated COX-2–positive (Huh7) and COX-2–negative (HepG2) liver cancer cell lines, using microarray analysis. Celecoxib treatment resulted in significantly altered expression levels of 240 and 403 transcripts in Huh7 and HepG2 cells, respectively. Confirmation of the microarray results was performed for selected genes by semiquantitative RT-PCR. A pathway/functional analysis of celecoxib-affected transcripts, using ingenuity pathway analysis and exploring biological association networks, revealed that celecoxib modulates expression of numerous genes involved in a variety of cellular processes, including cell death, cellular growth and proliferation, lipid metabolism, and energy turnover. Some of these processes were common for both HCC cell lines and seem to be coupled with NF-κB signaling, while others were cell-specific and possibly linked to the presence or the absence of COX-2 activity in the corresponding cell line. Many novel genes emerged from our analyses that were not previously reported to be affected by celecoxib. Further studies on selected celecoxib-responsive genes will establish if they may serve as potential molecular targets for more effective therapeutic strategies in HCC.Keywords
This publication has 25 references indexed in Scilit:
- Novel combination of Celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cellsCell Cycle, 2010
- Binding of LARP6 to the Conserved 5′ Stem–Loop Regulates Translation of mRNAs Encoding Type I CollagenJournal of Molecular Biology, 2010
- Coming together: liver fibrosis, collagen mRNAs and the RNA binding proteinExpert Review of Gastroenterology & Hepatology, 2009
- Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF-κBBiochemical Pharmacology, 2008
- Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemopreventionBiochemical Pharmacology, 2005
- Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX‐2 InhibitorsAnnals of the New York Academy of Sciences, 2004
- Expression of WISPs and of Their Novel Alternative Variants in Human Hepatocellular Carcinoma CellsAnnals of the New York Academy of Sciences, 2004
- COX‐2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX‐2 inhibitor celecoxibThe FASEB Journal, 2001
- Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine?European Journal of Cancer, 2001
- Isolation and Biochemical Characterization of the Human Dkk-1 Homologue, a Novel Inhibitor of Mammalian Wnt SignalingJournal of Biological Chemistry, 1999